A Phase 1, Multi-Center, Open-Label, Dose De-Escalation Study of the Oncolytic Virus Talimogene Laherparepvec (T-VEC) in Paediatric Patients with Advanced Extracranial Solid Tumors

被引：0
|
作者：
Moreno, L. [1 ]
Zhang, Y. [2 ]
Bhatta, S. [3 ]
机构：
[1] Hosp Univ Nino Jesus, Clin Res Programme, Madrid, Spain
[2] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA USA
[3] Amgen Inc, Global Dev, Thousand Oaks, CA USA
来源：
PEDIATRIC BLOOD & CANCER | 2016年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-0575
引用
收藏
页码：S211 / S211
页数：1
相关论文
共 50 条
  • [31] An open-label, multi-center, phase I/II, dose escalation study of IV TKM-080301 in subjects with advanced hepatocellular carcinoma
    Abou-Alfa, G. K.
    Yoon, J. H.
    Modiano, M.
    Ryoo, B. Y.
    Yau, T.
    Freilich, B.
    Knox, J.
    Ly, M.
    Ahmed, H.
    Gahir, S.
    Niforos, D.
    Kowalski, M.
    Kelley, R. K.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S22 - S22
  • [32] KontRASt: A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation
    Solomon, Benjamin
    Heist, Rebecca S.
    Tan, Daniel S. W.
    Cassier, Philippe A.
    Dooms, Christophe
    Van Cutsem, Eric
    Steuer, Conor E.
    Steeghs, Neeltje
    Schuler, Martin
    Gazzah, Anas
    Wermke, Martin
    Felip, Enriqueta
    Loong, Herbert H. F.
    Luken, Maria J. De Miguel
    Soo, Ross A.
    Jaeger, Ashley
    Xu, Kun
    Chen, Xueying
    Cui, Xiaoming
    Burks, Heather
    Farago, Anna F.
    Shimizu, Toshio
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [33] Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors
    Doerffel, Y.
    Kullmann, F.
    Lammert, F.
    Quietzsch, D.
    Schoefl, C.
    Schuppert, F.
    Weber, M.
    Baum, V.
    Berndt, I.
    Weiss, C.
    Lahner, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 237 - +
  • [34] A phase 1b, open-label, dose escalation and expansion study of demcizumab plus pembrolizumab in patients with locally advanced or metastatic solid tumors
    Johnson, Melissa
    Rasco, Drew
    Schneider, Brian
    Shu, Catherine
    Jotte, Robert
    Parmer, Hema
    Stagg, Robert
    Lopez, Juanita
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [35] A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
    Zonder, Jeffrey A.
    Mohrbacher, Ann F.
    Singhal, Seema
    van Rhee, Frits
    Bensinger, William I.
    Ding, Han
    Fry, John
    Afar, Daniel E. H.
    Singhal, Anil K.
    BLOOD, 2012, 120 (03) : 552 - 559
  • [36] A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors
    Tolcher, Anthony W.
    Wu, Xiaohua
    Zhang, Jian
    Barve, Minal A.
    Gabrail, Nashat Y.
    Sommerhalder, David
    Rivera, Ildefonso I. Rodriguez
    Wilks, Sharon
    Wu, Yong
    Liu, Rujiao
    Gao, Shuiping
    Valiyil, Akhilkrishna
    Sayi, Ntombizodwa
    Germa, Caroline
    Qi, Charlie
    Chen, Lei
    Yu, Steven
    Yao, Jenny
    Zhu, Xuelian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
    John Marshall
    Jimmy Hwang
    Ferry A. L. M. Eskens
    Herman Burger
    Shakun Malik
    Martina Uttenreuther-Fischer
    Peter Stopfer
    Mahmoud Ould-Kaci
    Roger B. Cohen
    Nancy L Lewis
    Investigational New Drugs, 2013, 31 : 399 - 408
  • [38] A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
    Mettu, Niharika B.
    Ulahannan, Susanna, V
    Bendell, Johanna C.
    Garrido-Laguna, Ignacio
    Strickler, John H.
    Moore, Kathleen N.
    Stagg, Robert
    Kapoun, Ann M.
    Faoro, Leonardo
    Sharma, Sunil
    CLINICAL CANCER RESEARCH, 2022, 28 (05) : 882 - 892
  • [39] Phase 1, open-label, dose-escalation study of M3814 ± avelumab radiotherapy (RT) in patients (pts) with advanced solid tumors.
    Bendell, Johanna C.
    Shafique, Michael Rahman
    Perez, Bradford
    Chennoufi, Sarah
    Beier, Frank
    Trang, Ky
    Antonia, Scott Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
    Marshall, John
    Hwang, Jimmy
    Eskens, Ferry A. L. M.
    Burger, Herman
    Malik, Shakun
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Ould-Kaci, Mahmoud
    Cohen, Roger B.
    Lewis, Nancy L.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 399 - 408
12345